Your browser doesn't support javascript.
loading
A prospective randomized study of efficacy of 2 treatment protocols in preventing recurrence of clinical signs in 51 male cats with obstructive idiopathic cystitis.
Nivy, Ran; Segev, Gilad; Rimer, Dar; Bruchim, Yaron; Aroch, Itamar; Mazaki-Tovi, Michal.
Affiliation
  • Nivy R; Veterinary Teaching Hospital and Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel.
  • Segev G; Veterinary Teaching Hospital and Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel.
  • Rimer D; Veterinary Teaching Hospital and Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel.
  • Bruchim Y; Veterinary Teaching Hospital and Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel.
  • Aroch I; Veterinary Teaching Hospital and Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel.
  • Mazaki-Tovi M; Veterinary Teaching Hospital and Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel.
J Vet Intern Med ; 33(5): 2117-2123, 2019 Sep.
Article in En | MEDLINE | ID: mdl-31400046
ABSTRACT

BACKGROUND:

Urethral obstruction (UO) is a common complication of feline idiopathic cystitis (FIC). Robust treatment recommendations to prevent its recurrence are scarce.

OBJECTIVES:

To evaluate meloxicam treatment for prevention of clinical recrudescence in male cats with obstructive FIC. ANIMALS Fifty-one client-owned cats.

METHODS:

Prospective, randomized clinical trial. Every male cat with FIC-associated UO was deemed eligible for the study and was recruited during hospitalization. After discharge, cats were treated with phenoxybenzamine and alprazolam for 2 weeks, with (24 cats) or without (27 cats) low-dose meloxicam (0.025 mg/kg/day PO) and monitored for 6 months.

RESULTS:

Cumulative number (%) of cats with recurrent UO at 10 days, 1-, 2-, and 6-months after discharge was 1 (2%), 2 (4%), 4 (8%), and 8 (16%), respectively. Overall, 12 (24%) cats experienced signs of recurrent FIC within 6 months, with (8 cats) or without (4 cats) concurrent UO. No difference in the cumulative incidence of UO within 6 months was detected with addition of meloxicam (odds ratio [95% confidence interval], 0.63 [0.13-2.97]; P = .70). All cats were alive at 6 months. CONCLUSIONS AND CLINICAL IMPORTANCE No clinical benefit was detected with the addition of low-dose meloxicam to phenoxybenzamine and alprazolam treatment for 2 weeks after discharge. Nevertheless, this study was underpowered to identify potential differences, and its findings must be corroborated in larger studies.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Urethral Obstruction / Cat Diseases / Anti-Inflammatory Agents, Non-Steroidal / Cystitis / Meloxicam Type of study: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Animals Language: En Year: 2019 Type: Article

Full text: 1 Database: MEDLINE Main subject: Urethral Obstruction / Cat Diseases / Anti-Inflammatory Agents, Non-Steroidal / Cystitis / Meloxicam Type of study: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Animals Language: En Year: 2019 Type: Article